Invitrogen and WARF sign licensing agreement

Under the terms of the agreement, Invitrogen will have the right to work with karyotypically normal human embryonic stem cells (hESCs) to develop novel research and drug discovery tools. With this agreement, Wisconsin Alumni Research Foundation (WARF) now has completed 24 licensing agreements for stem cell technologies with 18 companies.

Joydeep Goswami, vice president, stem cells and regenerative medicine at Invitrogen, said: “Having the ability to work with karyotypically normal hESCs through our license with WARF allows us to develop better technologies for research, such as more defined media and engineered stem cell lines. This agreement is another step in our strategy of pursuing advances in the high-growth area of regenerative medicine.”